Vicore Pharma extends research portfolio with new drug molecules
Vicore Pharma has today announced that it has developed new drug molecules that selectively stimulate the AT2 receptor (AT2R agonism) in the Renin-Angiotensin-System. Based on experience and learnings drawn from the company’s successful drug candidate, C21, the new molecules have been designed to address diseases in the metabolic and cardiovascular areas
This pressrelease has been published in Swedish on January 24, 2017.
On behalf of Vicore Pharma, Emeriti Bio—a Swedish company specialising in drug discovery—has designed and synthesized a new set of molecules using Vicore Pharma’s drug candidate C21 as a design template. After due optimisation and preclinical validations, the new compounds will be directed towards disease areas in the cardio-metabolic field. AT2R agonism has demonstrated strong results in animal experimental models in this field, and there are considerable unmet medical needs, e.g. in diabetic nephropathy and heart failure.
“We are confident with the preclinical data for C21 within the cardiovascular area. These new molecules open up new opportunities within larger indication areas besides the orphan drug space where C21 is being developed. We are particularly excited about the potential development possibilities in the cardio-metabolic space, and where fibrosis constitutes a significant portion of the pathology. For example, in diabetic nephropathy and HF-PEF[1]—indications for which we have strong preclinical data,” says Per Jansson, CEO of Vicore Pharma.
For further information, please contact:
Per Jansson, CEO
Tel: +46 (0)709-17 47 46 or e-mail per.jansson@vicorepharma.com
Klas Malmberg, CMO
Tel: +46 (0)703 07 20 29 or e-mail klas.malmberg@vicorepharma.com
About Vicore Pharma AB Based on selectively stimulating the AT2 receptor (AT2R), a key target in the currently hot research field of the Protective Renin-Angiotensin-System, Vicore Pharma has brought its lead compound named C21 to the clinic to treat devastating and rare diseases in the fields of fibrosis and inflammation. The compound has recently and uneventfully passed safety Phase I and will now primarily be brought forward for the treatment of idiopathic pulmonary fibrosis (IPF). www.vicorepharma.com
About Emeriti Bio AB Emeriti Bio is a newly started venture focusing on drug discovery and early drug development. The company is founded by senior researchers who have been involved in successful projects in AstraZeneca and other international pharma companies. The company is managed by Jan Fryklund, Ph.D., CEO, David Gustavsson, MD, PhD. Thomas Fex, PhD, Bengt Ohlsson, PhD and Björn Wallmark, PhD, chairman, all of whom possess more than 30 years of experience from the pharmaceutical industry. www.emeritipharma.se
[1] Heart failure with preserved ejection fraction.